StockGuru Profile IMNR
The Immune Response Corporation Presented at the Wall Street Analyst Forum Biotechnology and Healthcare Conference
Dr. Joseph O’Neill, President and CEO of the Immune Response Corporation , presented an overview of the Company’s immune-based therapies, currently in Phase II clinical trials, at the Wall Street Analyst Forum Biotechnology & Healthcare Conference (WSAF) in New York City.
The Company’s presentation to the WSAF took place on Thursday, December 7, 2006, at 11:10 am (EST). A live webcast of this presentation is available at http://www.investorcalendar.com/CEPage.asp?ID=111522%20. The online replay will be available for 30 days after the presentation.
Dr. O’Neill discusses the Company’s drug development pipeline, which includes NeruoVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of multiple sclerosis (MS) and IR103, for the treatment of human immunodeficiency virus (HIV). He also intended to provide an update on the 200-patient Phase IIb trial of NeuroVax(TM), which is proceeding with Accelsiors CRO & Consultancy Services.
Joseph F. O’Neill, M.D., M.S., M.P.H., joined the Board and was appointed Chief Executive Officer and President on October 31, 2005. Previously, he was the Deputy Coordinator and Chief Medical Officer in the Office of the U.S. Global AIDS Coordinator, Department of State from August 2003 to August 2005. Prior to joining the State Department, Dr. O’Neill served as the Director of the White House Office of National AIDS Policy from July 2002 to August 2003. Before his White House appointment, he served as Acting Director of the Office of HIV/AIDS Policy in the Department of Health and Human Services from 2001 to July 2002. Dr. O’Neill holds a faculty appointment at the Johns Hopkins University School of Medicine and maintains a clinical practice in the Johns Hopkins Hospital HIV/AIDS Program. He was also previously on the medical staff of the Chase Brexton Clinic, a community-based AIDS clinic in Baltimore.
Dr. O’Neill is a graduate of the School of Medicine of the University of California at San Francisco, and he holds degrees in business administration, public health, health and medical sciences from the University of California at Berkeley. He is board certified in internal medicine.
Stay tuned as we examine the valuation process of a company with two blockbuster drugs in the pipeline.
For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
MDodge@roiny.com
Source:
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080
Forward Looking Statement and Safe Harbor: Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .